About the Company
PDL BioPharma (known as Protein Design Labs prior to 2006) is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company. In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million. Protein Design Labs, founded in 1986 by cell biologist Laurence J. Korn and mathematician Cary Queen, was a pioneer in humanizing monoclonal antibodies. Its humanization technology was used in several monoclonal antibody drugs under licensing and collaboration agreements; such products included trastuzumab (Herceptin), bevacizumab (Avastin), and palivizumab (Synagis). It held its initial public offering in 1992 and by 1994 it had 13 compounds in its pipeline, and had partnered its lead product, the humanized monoclonal antibody daclizumab, with Roche under a license that called for a 15% royalty. Daclizumab became the first humanized monoclonal antibody approved for human use in 1997. PDL made another public offering in 2000, at the peak of the biotech IPO window that ran from 1998 to 2001. In 2003 it settled litigation with Genentech over royalty payments owed to PDL under their license agreement; annual royalties were anticipated at that time to be around $90M per year. These are the kinds of intellectual property and license agreements that PDL manages on behalf of its shareholders since 2008; in 2007 those royalty payments were around $220 million. One of the development programs that PDL had transferred to Facet was the use of daclizumab in indications it had never licensed to Roche, including multiple sclerosis. Facet partnered that development program with Biogen Idec which attempted a hostile buy out of Facet for $350M in 2009; Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year. The FDA approved daclizumab for multiple sclerosis in 2016 under the trade name Zinbryta. PDL Biopharma has filed for a liquidation under Delaware Law that was effective January 7 2021. The liquidation plan was approved by shareholders in October 2020.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PDLI News
PDL BioPharma Stock To Go Ex-dividend Monday (PDLI)
Shares are up 3.9% year to date as of the close of trading on Thursday. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al.
Treating Multiple Sclerosis With Monoclonal Antibodies
and DAC-HYP (produced by the PDL BioPharma Inc. high-yield 600 L process and therefore termed HYP) has been tested in three Phase I studies including 71 patients, and is currently used in the ...
ABVC BioPharma, Inc. (ABVC)
FREMONT, CA - (NewMediaWire) - May 09, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic ...
BiomX Announces the Appointment of Susan Blum to its Board of Directors
Ms. Blum also served in leadership roles at Orbitz Worldwide, Inc. (NYSE: OWW) from 2011 to 2013 and at Facet Biotech Corporation and PDL BioPharma, Inc. (Nasdaq: PDLI) from 2004 to 2010 ...
Sutro Biopharma Inc STRO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Sunshine Biopharma Inc.
1 Day SBFM -0.01% DJIA -0.15% Russell 2K 0.37% Health Care/Life Sciences -0.22% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...
TBPH Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized ...
Sunshine Biopharma Incorporated
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and ...
Aytu BioPharma Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
PDL BioPharma Stock To Go Ex-dividend Tomorrow (PDLI)
Shares are up 1.1% year to date as of the close of trading on Friday. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of Queen et al.
TBPH Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized ...
Sunshine Biopharma, Inc. (SBFM)
NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including ...
Loading the latest forecasts...